111 related articles for article (PubMed ID: 10390074)
1. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease.
Boughton BJ; Simpson AW
Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity.
Schirrmacher V; Müerköster S; Umansky V
Clin Cancer Res; 1998 Nov; 4(11):2635-45. PubMed ID: 9829726
[TBL] [Abstract][Full Text] [Related]
5. Generation of LAK cells in vitro in patients with acute leukemia.
Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T
Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived.
Boughton BJ; Simpson AW; Phaure TA; Beatty C
Cancer Immunol Immunother; 1995 Jul; 41(1):68-70. PubMed ID: 7641221
[TBL] [Abstract][Full Text] [Related]
10. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
[TBL] [Abstract][Full Text] [Related]
14. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
15. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
Archimbaud E; Bailly M; Doré JF
Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
[TBL] [Abstract][Full Text] [Related]
16. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy.
Margolin K; Forman SJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S33-8. PubMed ID: 10685656
[TBL] [Abstract][Full Text] [Related]
18. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
19. Donor regulatory T cells identified by FoxP3 expression but also by the membranous CD4+CD127low/neg phenotype influence graft-versus-tumor effect after donor lymphocyte infusion.
Hicheri Y; Bouchekioua A; Hamel Y; Henry A; Rouard H; Pautas C; Beaumont JL; Kuentz M; Cordonnier C; Cohen JL; Maury S
J Immunother; 2008; 31(9):806-11. PubMed ID: 18833007
[TBL] [Abstract][Full Text] [Related]
20. [Prolactin as pro-inflammatory cytokine--considerations on consolidated immunotherapy after high dosage therapy].
Hinterberger-Fischer M
Acta Med Austriaca Suppl; 2000; 52():16-20. PubMed ID: 11261272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]